Published in Ann Intern Med on April 20, 2010
Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med (2013) 4.64
Population-based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records. Ann Intern Med (2011) 3.38
A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancer-free by CT screening. J Thorac Oncol (2012) 1.63
Lung cancer screening practices of primary care physicians: results from a national survey. Ann Fam Med (2012) 1.33
CT scan screening for lung cancer: risk factors for nodules and malignancy in a high-risk urban cohort. PLoS One (2012) 1.12
Lung cancer in HIV Infection. Clin Lung Cancer (2011) 0.95
Screening tests: a review with examples. Inhal Toxicol (2014) 0.94
Nanocytology for field carcinogenesis detection: novel paradigm for lung cancer risk stratification. Future Oncol (2011) 0.90
Screening for cancer with molecular markers: progress comes with potential problems. Nat Rev Cancer (2012) 0.88
Update in lung cancer and mesothelioma 2012. Am J Respir Crit Care Med (2013) 0.87
Automated sputum cytometry for detection of intraepithelial neoplasias in the lung. Anal Cell Pathol (Amst) (2012) 0.81
Early lung cancer detection using the self-evaluation scoring questionnaire and chest digital radiography: a 3-year follow-up study in China. J Digit Imaging (2013) 0.81
Moving beyond the national lung screening trial: discussing strategies for implementation of lung cancer screening programs. Oncologist (2013) 0.80
Screening for lung cancer. CMAJ (2014) 0.80
Lung cancer screening: Computed tomography or chest radiographs? World J Radiol (2015) 0.79
[Opinion of the Austrian Society of Radiology and the Austrian Society of Pneumology]. Wien Klin Wochenschr (2013) 0.78
Tobacco smoking and methylation of genes related to lung cancer development. Oncotarget (2016) 0.78
The Effect of False-Positive Results on Subsequent Participation in Chest X-ray Screening for Lung Cancer. J Epidemiol (2016) 0.78
Update in lung cancer and oncological disorders 2010. Am J Respir Crit Care Med (2011) 0.78
Low-dose CT scan screening for lung cancer: comparison of images and radiation doses between low-dose CT and follow-up standard diagnostic CT. Springerplus (2013) 0.77
The use and misuse of positron emission tomography in lung cancer evaluation. Clin Chest Med (2011) 0.76
Procedures for risk-stratification of lung cancer using buccal nanocytology. Biomed Opt Express (2016) 0.76
Retracted Comparison of tumor markers using different detection devices. Onco Targets Ther (2015) 0.75
Helping Health Care Providers and Clinical Scientists Understand Apparently Irrational Policy Decisions. Cureus (2016) 0.75
Misleading statement in trial on false-positive results in lung cancer screening. Ann Intern Med (2010) 0.75
[Cumulative incidence of false-positive test results in lung cancer]. Praxis (Bern 1994) (2010) 0.75
False-positive test results in a study of lung cancer screening. Ann Intern Med (2010) 0.75
Biomarkers for early diagnosis, prognosis, prediction, and recurrence monitoring of non-small cell lung cancer. Onco Targets Ther (2017) 0.75
Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med (2011) 38.61
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA (2011) 9.13
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA (2011) 6.45
The National Lung Screening Trial: overview and study design. Radiology (2010) 6.43
Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med (2013) 5.92
A common standard for conflict of interest disclosure in addiction journals. Addiction (2009) 5.62
New models for large prospective studies: is there a better way? Am J Epidemiol (2012) 3.85
Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int (2008) 3.51
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51
Predictive accuracy of the Liverpool Lung Project risk model for stratifying patients for computed tomography screening for lung cancer: a case-control and cohort validation study. Ann Intern Med (2012) 3.45
Postpolypectomy colonoscopy surveillance guidelines: predictive accuracy for advanced adenoma at 4 years. Ann Intern Med (2008) 3.34
Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities. J Natl Cancer Inst (2010) 3.16
Using relative utility curves to evaluate risk prediction. J R Stat Soc Ser A Stat Soc (2009) 3.04
Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J Urol (2005) 3.01
Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst (2005) 2.82
Promoting healthy skepticism in the news: helping journalists get it right. J Natl Cancer Inst (2009) 2.82
Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer (2005) 2.79
Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med (2013) 2.66
Baseline characteristics of participants in the randomized national lung screening trial. J Natl Cancer Inst (2010) 2.50
Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials (2010) 2.38
Screening for prostate cancer with PSA testing: current status and future directions. Oncology (Williston Park) (2011) 2.26
Markers for early detection of cancer: statistical guidelines for nested case-control studies. BMC Med Res Methodol (2002) 2.26
Baseline chest radiograph for lung cancer detection in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. J Natl Cancer Inst (2005) 2.24
Evaluating markers for the early detection of cancer: overview of study designs and methods. Clin Trials (2006) 2.10
Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med (2009) 1.94
American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol (2010) 1.91
A cancer theory kerfuffle can lead to new lines of research. J Natl Cancer Inst (2014) 1.91
The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer (2013) 1.76
Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: a HuGE review. Am J Epidemiol (2002) 1.73
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2006) 1.64
Identifying genes that contribute most to good classification in microarrays. BMC Bioinformatics (2006) 1.60
Enrollment of racial and ethnic minorities in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. J Natl Med Assoc (2008) 1.60
Utilization and yield of surveillance colonoscopy in the continued follow-up study of the polyp prevention trial. Clin Gastroenterol Hepatol (2008) 1.58
National Lung Screening Trial findings by age: Medicare-eligible versus under-65 population. Ann Intern Med (2014) 1.56
Reported family history of cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol (2003) 1.52
Principles of cancer screening: lessons from history and study design issues. Semin Oncol (2010) 1.52
The word "cancer": how language can corrupt thought. BMJ (2013) 1.51
Death certificates provide an adequate source of cause of death information when evaluating lung cancer mortality: an example from the Mayo Lung Project. Lung Cancer (2008) 1.50
A perfect correlate does not a surrogate make. BMC Med Res Methodol (2003) 1.45
A population approach to precision medicine. Am J Prev Med (2012) 1.44
Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. Arch Intern Med (2007) 1.40
Lung cancer screening practices of primary care physicians: results from a national survey. Ann Fam Med (2012) 1.33
Selecting patients for randomized trials: a systematic approach based on risk group. Trials (2006) 1.33
American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. J Clin Oncol (2008) 1.29
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2007) 1.28
Estimating the cumulative risk of a false-positive test in a repeated screening program. Biometrics (2004) 1.27
Statistical issues in randomized trials of cancer screening. BMC Med Res Methodol (2002) 1.27
Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort. BMC Cancer (2009) 1.22
Use of lung cancer screening tests in the United States: results from the 2010 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev (2012) 1.22
Biomarkers, subgroup evaluation, and clinical trial design. Discov Med (2012) 1.21
U.S. primary care physicians' lung cancer screening beliefs and recommendations. Am J Prev Med (2010) 1.21
National Children's Study: update in 2010. Mt Sinai J Med (2011) 1.17
Plausibility of stromal initiation of epithelial cancers without a mutation in the epithelium: a computer simulation of morphostats. BMC Cancer (2009) 1.15
Simple adjustments for randomized trials with nonrandomly missing or censored outcomes arising from informative covariates. Biostatistics (2005) 1.15
Cancer screening campaigns--getting past uninformative persuasion. N Engl J Med (2012) 1.14
Surrogate endpoints: wishful thinking or reality? J Natl Cancer Inst (2006) 1.13
Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial. BJU Int (2007) 1.13
Instrumental variable analyses for observational comparative effectiveness research: the paired availability design. Ann Intern Med (2014) 1.13
Evaluation of markers and risk prediction models: overview of relationships between NRI and decision-analytic measures. Med Decis Making (2013) 1.13
The fallacy of enrolling only high-risk subjects in cancer prevention trials: is there a "free lunch"? BMC Med Res Methodol (2004) 1.11
Paradoxes in carcinogenesis: new opportunities for research directions. BMC Cancer (2007) 1.10
Prostate-specific antigen velocity and prostate cancer gleason grade and stage. Cancer (2007) 1.09
Diagnostic procedures after a positive spiral computed tomography lung carcinoma screen. Cancer (2005) 1.08
The transitive fallacy for randomized trials: if A bests B and B bests C in separate trials, is A better than C? BMC Med Res Methodol (2002) 1.08
Simple maximum likelihood estimates of efficacy in randomized trials and before-and-after studies, with implications for meta-analysis. Stat Methods Med Res (2005) 1.08
Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. Urology (2006) 1.07
Cancer screening in theory and in practice. J Clin Oncol (2005) 1.06
Likelihood of missed and recurrent adenomas in the proximal versus the distal colon. Gastrointest Endosc (2011) 1.02
Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial. J Urol (2006) 1.01
Does the source of death information affect cancer screening efficacy results? A study of the use of mortality review versus death certificates in four randomized trials. Clin Trials (2010) 1.01
Randomized trials, generalizability, and meta-analysis: graphical insights for binary outcomes. BMC Med Res Methodol (2003) 0.99
Estimating the cumulative risk of false positive cancer screenings. BMC Med Res Methodol (2003) 0.98
The prostate, lung, colorectal, and ovarian cancer screening trial and its associated research resource. J Natl Cancer Inst (2013) 0.98
Using observational data to estimate an upper bound on the reduction in cancer mortality due to periodic screening. BMC Med Res Methodol (2003) 0.98
Recruitment in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: the first phase of recruitment at Henry Ford Health System. Cancer Epidemiol Biomarkers Prev (2008) 0.98
5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review. BJU Int (2010) 0.97
Lung cancer screening with low-dose helical CT: results from the National Lung Screening Trial (NLST). J Med Screen (2011) 0.89
Cancer prevention and the American Society of Clinical Oncology. J Clin Oncol (2004) 0.88
Estimating the cumulative risk of a false-positive under a regimen involving various types of cancer screening tests. J Med Screen (2008) 0.87
Transparency and reproducibility in data analysis: the Prostate Cancer Prevention Trial. Biostatistics (2010) 0.86
Surrogate endpoint analysis: an exercise in extrapolation. J Natl Cancer Inst (2012) 0.86
Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901. J Cancer Surviv (2014) 0.85
Future directions for postdoctoral training in cancer prevention: insights from a panel of experts. Cancer Epidemiol Biomarkers Prev (2014) 0.85